Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787836 | 0.98 | MEN1 (0.49) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL21763101 | 0.95 | MEN1 (0.46) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL21788107 | 0.92 | PDK2 (0.41) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL21763102 | 0.91 | MEN1 (0.42) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL21763100 | 0.90 | PDK2 (0.42) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL21763412 | 0.90 | MEN1 (0.41) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL15183772 | 0.87 | MEN1 (0.46) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL16996413 | 0.87 | MEN1 (0.46) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL21787899 | 0.86 | PDE4D (0.40) | MEN1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL21763099 | 0.86 | PDK2 (0.41) | MEN1KMT2ALMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2022-01-06 | — | — | US | disclosed |
| US-20200075862-A1 | INDANE DERIVATIVES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | NR0B2, KCNJ2, TRRAP | MEN1 2154/4885KMT2A 1970/4885LMNA 2105/4885 |
| US-20200075862-A1 | INDANE DERIVATIVES AND THEIR USE IN ORGANIC ELECTRONICS | KCNJ2, KCNA2, CYP2J2 | MEN1 2274/4885KMT2A 1499/4885LMNA 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.